An observational study in Sars-CoV2, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-17.
Sponsored by University Hospital, Lille · Observational
Observational pilot single-center study aiming to determine the microbiota of critically ill patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical critically ill controls with no SARS-CoV-2 infection.
Observational pilot single-center study aiming to determine the microbiota of critically ill patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical critically ill controls with no SARS-CoV-2 infection.
Respiratory and fecal microbiota (microbial and fungal) will be determined in COVID-19 patients on bronchoalveolar lavage and rectal swab.
Inflammatory biomarkers will also be measured in COVID-19 patients.
Characteristics of study patients will be collected at ICU admission and during ICU stay.
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's enrollment of 34 is below the median of 203 across 688 observational studies indexed under Pneumonia.
Browse Pneumonia studies →University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients suspected of SARS-CoV2 infection and admitted in ICU
For the Covid-19 Group: with a confirmed severe lung infection with CoV2-SARS-Cov2 admitted to the ICU.
For the Control Group:
Exclusion Criteria:
Critically ill patients with SARS-CoV-2 infection
Historical critically ill patients with no SARS-CoV-2 infection
Composition of the fecal bacterial and fungal microbiota
relative abundances and diversity indices
Time frame: At 28 days
Analysis of the faecal microbiota from rectal swab
Alterations in fecal microbiota composition (including virose, bacteria and fungi) in COVID-19 patients compared with controls
Time frame: at baseline and every 7 days during 28 days
Analysis of the respiratory microbiota from the bronchoalveolar lavage liquid
Alterations in respiratory microbiota composition (including virose, bacteria and fungi) in COVID-19 patients compared with controls
Time frame: at baseline and every 7 days during 28 days
Serum inflammatory markers changes
Changes in blood, c-reactive protein, leucocyte, lymphocyte from baseline
Time frame: at 28 days,
Inflammatory markers changes
changes in Cytokine/ chemokine from baseline
Time frame: at 28 days,
Mortality
death
Time frame: at 28 days,
mechanical ventilation free days
Number of days alive without mechanical ventilation
Time frame: at 28 days,
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille